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Introduction:  Splanchnic  mast  cells  increase  in  chronic  liver  and  in  acute-on-chronic  liver  dis-
eases. We  administered  Ketotifen,  a  mast  cell  stabilizer,  and  measured  the  mast  cells  in  the
splanchnic organs  of  cholestatic  rats.
Material  and  Methods:  These  groups  were  studied:  sham-operated  rats  (S;  n  =  15),  untreated
microsurgical  cholestasic  rats  (C;  n  =  20)  and  rats  treated  with  Ketotifen:  early  (SK-e;  n  =  20  and
CKe; n  =  18),  and  late  (SK-l;  n  =  15  and  CK-l;  n  =  14).
Results:  The  cholestatic  rats  showed  systemic  and  splanchnic  impairments,  such  as  ascites,
portal hypertension,  and  biliary  proliferation  and  fibrosis.  The  rats  also  showed  a  splanchnicPlease  cite  this  article  in  press  as:  Aller  M-Á,  et  al.  Mast  cell-mediated  splanchnic  cholestatic  inflammation.  Clin  Res
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increase of  TNF-,  IL-1  and  MCP-1,  and  a  reduction  of  IL-4,  IL-10  and  antioxidants.  An  increase
of VEGF  in  the  ileum  and  mesenteric  lymphatic  complex  was  associated  with  a  liver  reduction  of
TGF-1. Ketotifen  reduces  the  degree  of  hepatic  insufficiency  and  the  splanchnic  inflammatory
mediators,  as  well  as  VEGF  and  TGF-ß1  levels.  Ketotifen  also  reduces  the  connective  tissue
Abbreviations: ALT, alanine aminotransferase; AP, alkaline phosphatase; AST, aspartate aminotransferase; FGF, fibroblastic growth factor;
BW, body weight; CTMCs, connective tissue mast cells; HDL-C, high density lipoprotein; LDL-C, low density lipoproteins; LW, liver weight;
MMCs, mucosal mast cells; MCP-1, monocyte chemoattractant protein-1; NEFAs, non-esterified fatty acids; PP, Portal vein pressure; RMCP-II,
rat mast cell proteinases 2; SW, spleen weight; TB, total bilirubin; TGF-1, Transforming growth factor beta 1; Treg, regulatory T-cell; VLDL,
very low density lipoproteins; VCU, villus-crypt units; VEGF, vascular endothelium growth factor.
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mast  cells  in  the  mesenteric  lymphatic  complex  of  cholestatic  rats,  while  increases  the  hepatic
mucosal mast  cells.
Conclusions:  In  cholestatic  rats,  Ketotifen  improves  liver  function  and  ascites,  and  also  reduces
pro-inflammatory  mediators  in  the  splanchnic  area.  The  decrease  in  connective  tissue  mast  cells
in the  mesenteric  lymphatic  complex  due  to  the  administration  of  Ketotifen  would  lead  to  the
improvement  of  the  inflammatory  splanchnic  response,  and  consequently  the  abovementioned
complications.















































































epatic  dysfunction  related  to  fibrosis  or  cirrhosis  would
ggravate  the  grade  of  splanchnic  and  systemic  inflamma-
ion  characteristic  of  portal  hypertension.  As  a  result,  this
ould  increase  the  incidence  of  complications  [1,2].  It  has
een  recognized  that  splanchnic  mast  cells  are  present
nder  normal  and  pathological  liver-related  conditions  in
oth  humans  and  experimental  animals  [3—9].
It  was  suggested  that  mast  cells,  involved  in  both  innate
nd  adaptive  immunity  [10,11],  could  be  correlated  with
he  evolution  of  experimental  portal  hypertension  [2]  and
xperimental  hepatic  chronic  disease  [1,12].  This  is  the  rea-
on  why  we  have  studied  the  hepatic-spleen-intestinal  and
esenteric  lymph  node  distribution  of  mucosal  mast  cells
MMCs)  and  connective  tissue  mast  cells  (CTMCs)  in  an  exper-
mental  model  of  chronic  liver  insufficiency  secondary  to
icrosurgical  obstructive  cholestasis  in  the  rat  [13].  It  can
e  accepted  that  this  experimental  model  evolves  in  two
hases.  A  first  or  ‘‘compensated’’  phase  and  a  rapidly  pro-
ressive  ‘‘decompensated’’  phase,  from  the  sixth  week  of
ostoperative  evolution,  resulting  in  the  development  of
scites  [14].
Since  Ketotifen  is  a  mast  cell  stabilizer  drug  [15], we
dministered  it  to  the  obstructive  cholestatic  rats,  either
4  hours  before  the  intervention  or  during  the  postoperative
eriod  (8  weeks)  to  prevent  decompensation  of  the  rats,  or
rom  the  sixth  week  of  p.o.  through  the  eighth  week  to  treat
ecompensation  and  evaluate  its  effect  on  the  potential
hanges  in  the  splanchnic  mast  cell  distribution.
aterials and methods
e  used  male  Wistar  rats,  weighing  between  230  and  270  g
rom  the  Vivarium  of  the  Complutense  University  of  Madrid.
he  experimental  procedures  employed  in  this  study  were
erformed  in  accordance  with  the  Ethical  Guidelines  from
uropean  Community  Council  Directive  (86/609/EEC)  and
ublished  in  Spanish  Royal  Decree  53/2013.  All  procedures
ere  approved  by  the  Complutense  University  Animal  Wel-
are  Committee.
xperimental designPlease  cite  this  article  in  press  as:  Aller  M-Á,  et  al.  Mast  cel
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he  animals  were  randomly  divided  into  six  groups:  sham-
perated  (S;  n  =  15),  rats  with  microsurgical  cholestasis  (C;





al  cholestatic  rats  (CK-e;  n  =  18);  both  of  these  groups  were
dministered  Ketotifen  early  on,  starting  24  hours  before  the
peration  until  they  were  sacrificed  8  weeks  post-operation;
ham-operated  (SK-l;  n  =  15)  and  microsurgical  cholestatic
ats  (CK-l;  n  =  14):  both  of  these  groups  were  administered
etotifen  late,  starting  the  sixth  week  after  the  opera-
ion  until  they  were  sacrificed  8  weeks  post  operation.  In
ssence,  early  administration  of  Ketotifen  means  that  the
nimals  receive  Ketotifen  throughout  the  preoperative  and
ostoperative  periods.  On  the  contrary,  late  administration
f  Ketotifen  means  that  the  rats  only  receive  Ketotifen  dur-
ng  the  last  two  weeks  of  the  postoperative  period.  All
he  animals  were  sacrificed  by  anaesthesia  overdose  at  8
eeks  post  operation.  Body  (BW),  liver  (LW)  and  spleen  (SW)
eights  were  determined.
etotifen treatment
or  the  stabilization  of  the  mast  cells,  Ketotifen  was  added
o  the  drinking  water.  The  compound  was  dissolved  in  water
t  an  initial  concentration  of  0.1  mg/mL,  allowing  an  esti-
ated  dosage  of  10  mg/kg  per  day  (based  on  a  mean  water
onsumption  of  30  mL/day).  During  the  treatment  period,
nimals  were  housed  individually.  The  amount  of  water
runk  by  each  rat  was  monitored  daily  and  the  concentration
f  Ketotifen  adjusted  to  ensure  the  desired  dosage  [16].
urgical  procedure
ats  were  anesthetized  with  Ketamine  Hydrochloride
100  mg/kg)  and  Xylazine  (12  mg/kg)  i.m.  In  S-rats,  the  bile
uct  and  its  lobular  branches  were  dissected.  The  micro-
urgical  cholestatic  rats  underwent  an  extrahepatic  biliary
ract  resection  using  a  binocular  operatory  microscope
Zeiss,  OPMI  1-FR,  Madrid,  Spain),  as  previously  described
13]. Buprenorphine  (0.05  mg/Kg/8  h  s.c.)  was  administered
or  analgesia  the  first  day  of  the  postoperative  period,  and
ntibiotic  and  vitamin  K  were  administered  during  all  the
.o.,  as  previously  described  [13,14].
ortosystemic collateral circulation study
ethod
he  splenorenal,  gastroesophageal,  and  colorectal  areas,
here  collateral  venous  circulation  normally  develops,  werel-mediated  splanchnic  cholestatic  inflammation.  Clin  Res
e.2019.02.001
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Mast  cell-mediated  splanchnic  cholestatic  inflammation  
Portal vein pressure measurements
Portal  vein  pressure  (PP)  was  measured  by  inserting  a  fluid-
filled  20-gauge  needle  into  the  splenic  parenchyma  [18].
Previous  studies  have  demonstrated  the  excellent  correla-
tion  between  splenic  pulp  pressure  and  PP  [19].
Gross mesenteric venous vasculopathy study
Three  grades  of  mesenteric  venous  vasculopathy  were  con-
sidered,  as  previously  described;  grade  0:  normal;  grade  1:
after  the  Pringle  maneuver,  and  grade  2:  spontaneous  [6,20].
Serum biochemical test
Blood  samples  were  drawn  by  puncture  of  the  infra-
hepatic  inferior  vena  cava.  The  serum  was  frozen  at
−40 ◦C  until  total  bilirubin  (TB),  alkaline  phosphatase  (AP),
aspartate  aminotransferase  (AST),  alanine  aminotransferase
(ALT),  albumin  and  Cholesterol,  Triglicerides,  high  den-
sity  lipoprotein  (HDL-C),  low  density  lipoproteins  (LDL-C),
very  low-density  lipoproteins  (VLDL)  and  non-esterified  fatty
acids  (NEFAs)  were  assayed  in  an  autoanalizer.
TNF-, IL-1, IL-4, and IL-10 splanchnic levels
Samples  from  the  distal  ileum  (1  cm  from  the  ileo-caecal
junction),  the  liver,  the  spleen,  and  the  mesenteric  lymph
complex  were  quickly  taken,  frozen  on  dry  ice,  and
transferred  to  5  mL  polypropylene  tubes  (Falcon;  Becton
Dickinson,  Lincoln  Park,  NJ)  containing  lysis  buffer  (4 ◦C)
at  a  ratio  of  10  mL  buffer/L  g  of  wet  tissue.  Lysis  buffer
was  1 mmol/L  phenylmethylsulfonyl  fluoride  (PMSF;  Sigma
Chemical  Company,  Madrid,  Spain),  and  1  mg/mL  pepstatin  A
(Sigma  Chemical  Company),  aprotinin  (Sigma  Chemical  Com-
pany),  anti-pain  (Sigma  Chemical  Company),  and  leupeptin
in  13  phosphate-buffered  saline  solution  with  pH  7.2  (Bioflu-
ids,  Rockville,  MD)  containing  0.05%  sodium  azide  (Sigma
Chemical  Company).  The  samples  were  homogenized  for
30  s  with  an  electrical  homogenizer  (Polytron;  Brinkmann
Instruments,  Westminster,  NY)  at  maximum  speed,  and
immediately  frozen  in  liquid  nitrogen  at  —80 ◦C.  After  thaw-
ing  at  4 ◦C,  the  aggregates  were  pelleted  at  3000  g  (4 ◦C).
Finally,  the  in  these  homogenates  were  assayed  the  quan-
titative  levels  of  rat  TNF-, IL-1, IL-4,  and  IL-10,  in  six
animals  of  each  group  (sham-operated  and  cholestatic  rats)
using  commercially  available  enzyme  linked  immunosorbent
assay  specific  kits  (BioNOVA  Cientifica  Ltd.  Madrid,  Spain).
Histopathologic examinations
Five  m-thick  samples  of  the  middle  liver  lobe  were  stained
with  hematoxylin  and  eosin  (H&E)  and  Sirius  red.  An  imagePlease  cite  this  article  in  press  as:  Aller  M-Á,  et  al.  Mast  cel
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analysis  system  was  used  to  assess  fibrosis  grade  of  the
hepatic  tissue  from  the  sections  stained  with  Sirius  red  com-







mmunohistochemistry  for  rat  mast  cell
roteinases  2  and  connective  mast  cell  counts
mmunodetection  of  RMCP-II,  specific  marker  of  mucosal
ast  cells  (MMC)  in  the  rats,  was  carried  out  on
araformaldehyde-fixed  sections  using  a  specific  rat  mono-
lonal  antibody  (1:500;  Moredun  Animal  Health,  Edinburgh,
K)  [22].  The  connective  tissue  mast  cells  (CTMC)  were
etected  by  toluidine  blue  staining  protocol  [23].  Positively
tained  mast  cells  were  counted  in  three  to  five  sections
f  ileum  per  animal.  Seven  to  ten  well  oriented  villus-
rypt  units  (VCU)  were  examined  per  ileum  section.  Mucosal
C  and  connective  tissue  MC  counting  was  normalized  for
he  surface  area  of  liver,  lymphatic  nodes  and  spleen,  as
valuated  in  digital  images.  Cell  counting  was  performed
sing  an  Axioskop  40  microscope  [Carl  Zeiss,  Jena,  Germany;
quipped  with  a  digital  camera,  Zeiss  AxioCam  MRm;  image
nalysis  software:  Zeiss  Axiovision  Release  4.8.1].  Analyses
f  all  morphological  data  were  performed  blinded  to  prevent
bserver  bias  [23].
tatistical analysis
he  results  are  expressed  as  the  mean  ±  the  standard  devi-
tion.  Student’s  t  test  for  independent  data  or  analysis  of
ariance  (ANOVA)  and  the  Duncan  test  were  used  when
ppropriate  for  comparison  of  the  variables  between  the
ifferent  groups  studied.  The  results  were  considered  sig-
ificant  if  P  <  0.05.
esults
he  cholestatic  rats  displayed  ascites,  increased  por-
al  pressure  (P  <  0.001),  mesenteric  venous  vasculopa-
hy  and  portosystemic  collateral  circulation  with  hep-
tosplenomegaly  (P  <  0.001),  testicular  atrophy  (P  <  0.01),
holesterol  (P  <  0.001),  triglycerides  (P  <  0.05)  and  LDL;
 <  0.001)  and  VLDL;  P  <  0.001)  (Table  1),  hyperbilirubinemia
P  <  0.001),  increased  AP  (P  <  0.001),  bile  acids  (P  <  0.001),
STe  (P  < 0.001)  (Table  2).  On  the  contrary,  hypoproteinemia
P  <  0.001)  and  hypoalbuminemia  (P  <  0.001)  and  reduced
oncentration  of  HDL;  P  <  0.05)  (Table  3)  were  shown  in
hese  rats.  Antioxidants  mediators  reduced  in  the  ileum
P  <  0.01),  the  liver,  and  in  the  mesenteric  lymph  nodes  in  the
holestatic  rats  (Table  4),  whereas  IL-1 was  reduced  in  the
leum  (P  <  0.05)  and  mesenteric  lymph  nodes,  but  increased
n  the  liver  (P  <  0.05)  (Table  5).  IL-10  increased  in  the  ileum
P  <  0.05);  IL-4  increased  in  the  ileum  (P  <  0.05)  and  in  the
iver;  IL-13  and  IL-17A  increased  in  the  ileum,  but  were
educed  in  the  mesenteric  lymph  nodes  (Table  4).  Mono-
yte  chemoattractant  protein-1  (MCP-1)  increased  in  the
leum  (P  <  0.05),  and  was  reduced  in  the  mesenteric  lymph
odes  and  liver  (P  <  0.01)  (Table  5).  Transforming  growth
actor  beta  1  (TGF-1) increased  in  the  ileum  and  liver,
ut  was  reduced  in  the  mesenteric  lymph  nodes  (Table  2).
he  cholestatic  rats  showed  hepatic  necrosis  associatedl-mediated  splanchnic  cholestatic  inflammation.  Clin  Res
e.2019.02.001
ith  epithelial  biliary  proliferation  and  fibrosis  (P  <  0.001)
Fig.  1).
The  treatment  with  Ketotifen  during  the  entire  post-
perative  period  of  the  rats  with  cholestasis  reduced  ascites,
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Table  1  Increase  in  body  weight  (BW),  liver  weight  (LW),  spleen  weight  (SW),  testes  weight  (TW),  portal  pressure  (PP)  and
ascites in  sham-operated  rats  (S),  in  microsurgical  cholestatic  (C)  rats,  in  sham-operated  (SK-e)  and  microsurgical  rats  (CK-e),
which were  early  administered  Ketotifen  and  in  sham-operated  (SK-l)  and  microsurgical  rats  (CK-l)  that  were  late  administered
Ketotifen.
Groups    BW  (g)  LW  (g)  SW  (g)  TW  (g)  PP  (mmHg)  ASCITES  (ml)
S  n  =  15  153’66  ±  20’06  13’83  ±  2’27  0’87  ±  0’09  3’64  ±  0’28  8’25  ±  2’33  -------------
C n  =  20  51’82  ±  31’26a 26’01  ±  5’22a 2’03  ±  0’41a 2’90  ±  0’55a 13’43  ±  2’33a 6’88  ±  5’35
SK-e n  =  20  113’48  ±  34’64a,  b 12’13  ±  0’87b 0’72  ±  0’09b 3’56  ±  0’16oo 10’29  ±  2’12o**  -------------
CK-e n  =  18  39’81  ±  24’65a,  c 17’90  ±  3’88c,  d**  1’57  ±  0’39a,  c,  d 2’23  ±  0’85a,  coo 11’28  ±  5’80a 3’71  ±  2’70
SK-l n  =  15  161’00  ±  39’28  13’41  ±  1’37  0’84  ±  0’15  3’78  ±  0’37  7’02  ±  1’83  -------------
CK-l n  =  14  87’08  ±  37’05++  28’22  ±  5’23d 2’11  ±  0’32d 3’10  ±  0’4d 15’04  ±  2’63d 4’01  ±  3’18
Mean ± SD. Mean ± SD. ***P  < 0’001. Statistically significant value in regards to S; ooo: statistically significant value in relation to C;
P < 0’001: statistically significant value in relation to SK-e; +++P < 0’001: statistically significant value in relation to SK-l.
a P < 0’001. Statistically significant value in regards to S.






































































c P < 0’001: statistically significant value in relation to SK-e.
d P < 0’001: Statistically significant value in relation to SK-l.
ody  weight,  the  hepatosplenomegaly,  total  and  direct
ilirubin  and  bile  acid  concentrations  whereas  HDL  levels
nd  total  protein  were  increased  (Tables  1,  2  and  3).  Keto-
ifen  also  reduced  the  levels  of  MCP-1  in  the  liver,  TNF- in
he  ileum  and  liver  (P  <  0.05),  IL-17  A  and  IL-1 in  the  ileum
P  <  0.05)  whereas  concentrations  of  IL-4  and  IL-10  in  the
iver  and  IL-13  in  the  ileum  increased  (Table  5).
Rats  with  cholestasis  treated  with  Ketotifen  starting  at
ix  weeks  until  they  were  sacrificed  at  eight  weeks  post-
peration  showed  an  increase  in  body  weight  (P  <  0.01),  and
 reduction  in  ascites,  splenomegaly  (P  <  0.001),  testicu-
ar  atrophy  (P  <  0.01)  (Table  1),  collateral  circulation,  and
ntestinal  mesenteric  vasculopathy.  Ketotifen  reduced  the
erum  index  of  AST/ALT  (P  <  0.001),  LDH  (P  <  0.01)  and  cre-
tinine  (P  <  0.001)  (Table  2);  while  (P  <  0.05)  HDL  and  total
rotein  levels  increased  (Tables  1,  2  and  3).  Ketotifen  also
educed  (P  <  0.001)  the  levels  of  MCP-1  in  the  liver,  ileum,
nd  mesenteric  lymph  nodes,  and  reduced  TNF- in  the
leum  and  mesenteric  lymph  nodes,  and  IL-4,  IL-13,  and  IL-
7  A  in  the  liver  (P  <  0.01)  (Table  5).  Lastly,  Ketotifen  reduced
P  <  0.001)  VEGF  in  all  the  splanchnic  organs  studied,  while
oncentrations  of  TGF-1 in  the  liver  (P  <  0.05)  and  ileum
Table  1)  increased.
Ketotifen  administered  during  the  entire  post-operative
eriod  increased  (P  <  0.05)  liver  fibrosis,  whereas  Ketotifen
dministered  from  only  week  six  to  eight  did  not  produce
ny  effect  (Fig.  1).
planchnic mast cell density
ucosal  (MMC)  and  connective  tissue  mast  cells  (CTMC)  were
etermined  in  liver,  spleen,  mesenteric  lymph  nodes  and
leum.  The  concentration  of  connective  tissue  mast  cells
nd  most  importantly,  mucosal  mast  cells,  change  in  the
planchnic  area  in  the  cholestatic  rats  (Figs.  2−4).
CTMC  in  the  mesenteric  lymphatic  complex  showed  an
ncrease  in  relation  to  SKe  (P  <  0.05  )  and  SKl  (P  <  0.01)Please  cite  this  article  in  press  as:  Aller  M-Á,  et  al.  Mast  cel
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Fig.  2a).  Ketotifen-reduced  CTMC  in  the  lymph  nodes  of
he  cholestatic  rats  ketotifen  administered  continuously
pre-  and  postoperatory;  CKe)  as  in  a  late  period  of  the




erences  (Fig.  2a).  MMC  in  the  mesenteric  lymph  nodes  also
ncreased  in  the  cholestatic  rats  and  both  types  of  treatment
ith  Ketotifen  produced  a  reduction,  although  this  reduc-
ion  is  not  statistically  significant  in  regards  to  the  control
holestatic  rats  (Fig.  2a).
In  the  liver,  no  statistically  significant  differences  of
TMC  were  found  between  the  animals  treated  with  Keto-
ifen  and  the  cholestatic  rats  without  treatment.  This  result
s  paradoxical  because  cholestasis  in  these  animals  caused
n  increase  (P  <  0.05)  compared  to  the  sham-operated  ani-
als  (Fig.  2b).  Similar  results  were  found  in  the  MMC  liver.  In
his  case,  the  animals  with  cholestasis  showed  an  increase
P  <  0.05)  when  compared  to  sham-operated  animals  and
hose  treated  with  Ketotifen.  Neither  of  the  two  admin-
stration  methods  showed  statistically  significant  values  in
egards  to  the  cholestatic  rats  (Fig.  2b).
The  administration  of  Ketotifen  to  the  cholestatic  rats
id  not  change  CTMC  concentration  in  the  ileum  compared
o  the  treated  cholestatic  rats  (Figs.  4a  and  3).  Furthermore,
he  density  of  MMC  in  the  ileum  did  not  change  when  Keto-
ifen  was  administered  to  the  rats  with  cholestasis  (C),  even
hough  cholestasis  is  a  factor  associated  with  the  increase
P  <  0.05)  of  MMC  in  relation  to  the  sham-operated  animals
Figs.  3  and  4a).
In  the  spleen,  CTMC  increased  in  the  cholestatic  rats,
ither  those  treated  or  not  treated  with  Ketotifen  when
ompared  to  the  sham-operated  rats.  This  CTMC  increase
as  only  statistically  significant  (P  <  0.01)  in  the  cholestatic
ats  that  were  administered  Ketotifen  during  the  late  potop-
rative  period  (CKl)  (Figs.  3  and  4b).  In  addition,  the  values
f  MMC  showed  an  increase  in  the  spleen  of  the  cholestatic
ontrol  rats  (C)  and  in  those  treated  with  Ketotifen  (CKe
nd  CKl)  in  regards  to  the  sham-operated  animals.  However,
his  increase  was  only  statistically  significant  (P  <  0.05)  in
he  control  cholestatic  rats  (C)  (Figs.  3  and  4b).
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ast  cells  in  rodents  are  divided  into  two  types  based  on
rotease  expression  patterns:  the  connective  tissue  mast

































































Table  2  Total  bilirubin  (TB);  direct  bilirubin  (DB),  alkaline  phosphatase  (AP),  bile  acids  (BA),  aspartate  aminotransferase  (AST),  alanine  aminotransferase  (ALT),  AST/ALT
index, gamma-glutamiltranspeptidase  (GGT),  lacticodehidrogenase  (LDH),  total  proteins  (TP),  albumin  (Alb)  and  factor  growth  transforming  ß1  in  sham-operated  rats  (S),  in
microsurgical cholestatic  (C)  rats,  in  sham-operated  (SK-e)  and  microsurgical  rats  (CK-e),  which  were  early  administered  Ketotifen  and  in  sham-operated  (SK-l)  and  microsurgical
rats (CK-l)  that  were  late  administered  Ketotifen.
Groups TB (mg/dL) DB (mg/dL) AP (U/L) BA (mol/L) AST (U/L) ALT (U/L) AST/ALT GGT (U/L) LDH (U/L) TP (g) Alb (g/dL) TGF-1  (g/dL)
S (n = 15) 0’09 ± 0’04 0’001 ± 0’01 112’34 ± 34’12 6’78 ± 2’92 146’66 ± 77’31 53’50 ± 29’76 2’92 ± 1’61 — 1013’00 ± 497’81 5’97 ± 0’38 3’02 ± 0’14 45’83 ± 42’63
C  (n = 20) 8’17 ± 1’76a 4’92 ± 1a 284’88 ± 69’30a 42’84 ± 17,61a 245’07 ± 78’53a 27’32 ± 11’36** 10’07 ± 3’87a — 967’76 ± 388’69 4’28 ± 0’96a 1’62 ± 0’41a 34’46 ± 14’00
SK-e  (n = 20) 0’86 ± 2’60 0’44 ± 1’52 139’62 ± 128’93 7’91 ± 5’24 130’23 ± 84’01 37’85 ± 31’03 3’77 ± 1’47 4’00 ± 10’51 1181’07 ± 1318’81 5’83 ± 0’45 2’71 ± 0’43 44’23 ± 66’25
CK-e  (n = 18) 7’81 ± 2’94b 4’38 ± 1’68b 336’35 ± 109’90b 31’93 ± 12’28b 249’00 ± 82’84b 27’94 ± 13’61 12’98 ± 6’91b 37’88 ± 19’32 541’28 ± 265’52 5’04 ± 0’88oo 1’60 ± 0’49b 33’85 ± 16’53
SK-l  (n = 15) 0’63 ± 2’16 0’31 ± 1’26 118’25 ± 109’10 5’67 ± 6’02 106’11 ± 43’34 48’05 ± 30’12 2’60 ± 1’32 3’20 ± 8’7 741’53 ± 655’64 5’81 ± 0’45 2’77 ± 0’37 31’77 ± 53’01
CK-l  (n = 14) 7’91 ± 2’08d 4’16 ± 1’09d 550’80 ± 138’94d 51’70 ± 28’91d 320’76 ± 102’92c 84’84 ± 22’89c 3’86 ± 1’01 31’64 ± 10’86d 621’35 ± 215’89 4’81 ± 0’92d 1’22 ± 0’28d 41’95 ± 21’68
Mean ± SD. **P<0.01: statistically significant value in regards to S Group.
a P < 0’001. Statistically significant value in regards to S.
b Statistically significant value in relation to C.
c P < 0.01.




























































Table  3  Cholesterol,  Triglicerides,  high  density  lipoprotein  (HDL-C),  low  density  lipoproteins  (LDL-C),  very  low  density  lipoproteins  (VLDL)  and  non-esterified  fatty  acids
(NEFAs) in  sham-operated  rats  (S),  in  microsurgical  cholestatic  (C)  rats,  in  sham-operated  (SK-e)  and  microsurgical  rats  (CK-e),  which  were  early  administered  Ketotifen  and  in
sham-operated (SK-l)  and  microsurgical  rats  (CK-l)  that  were  late  administered  Ketotifen.
Groups  Cholesterol  (mg/dl)  Triglicerides  (mg/dl)  HDL-C  (mmol/L)  LDL-C  (mmol/L)  VLDL-C  (mmol/L)  NEFAs  (mmol/L)
S  (n  =  15)  63’30  ±  10’19  161’33  ±  53’53  0’78  ±  0’11  0’27  ±  0’05  0’57  ±  0’22  1’39  ±  0’88
C◦  ◦ (n  =  20)  143’31  ±  65’47c 157’69  ±  53’72  0’65  ±  0’16a 2’69  ±  1’43c 0’35  ±  0’21  0’61  ±  0’20b
SK-e  (n  =  20)  70’30  ±  232’13  120’07  ±  43053  0’81  ±  0’11  0’52  ±  0’85  0’48  ±  0’27  0’64  ±  0’22
CK-e (n  =  18)  158’30  ±  75’93e 165’58  ±  75’94d 0’92  ±  0’23d 0’48  ±  0’27  0’42  ±  0’36  0’49  ±  0’17
SK-L (n  =  15)  62’12  ±  26’72  145’32  ±  43’25  0’79  ±  0’13  0’44  ±  0’71  0’38  ±  0’16  0’65  ±  0’32
CK-l (n  =  14)  151’57  ±  72’84f 170’83  ±  93’68  0’89  ±  0’22  2’83  ±  1’4f 0’25  ±  0’44  0’53  ±  0’16
Mean ± SD.
◦ ◦ P < 0.01.
a P < 0.05.
b P < 001.
c P < 0’001: Statistically significant value in regards to S.
d P < 0.05.
e P < 0.001: Statistically significant value in relation to C.

































































Table  4  Catalase  Glutation-transferase  and  Glutation  peroxidase  in  the  ileum,  the  mesenteric  lymph  nodes  and  the  liver  in  in  sham-operated  rats  (S),  in  microsurgical
cholestatic (C)  rats,  in  sham-operated  (SK-e)  and  microsurgical  rats  (CK-e),  which  were  early  administered  Ketotifen  and  in  sham-operated  (SK-l)  and  microsurgical  rats  (CK-l)
that were  late  administered  Ketotifen.
Catalase  (mol/mg) Glutation-transferase  (mol/mg) Glutation  peroxidase  (mol/mg)
Groups  Ileum  Mesenteric  nodes Liver  Ileum  Mesenteric  nodes Liver  Ileum  Mesenteric  nodes Liver
S  (n  =  6)  1’05  ±  0’40  2’24  ±  0’50  3’18  ±  0’08  3326’70  ±  1025’33  718’35  ±  135’08  4882’69  ±  474’24  1000’57  ±  136’63  876’13  ±  40’45  5450’40  ±  346’41
C (n  =  6)  1’97  ±  0’44  1’04  ±  0’11  2’84  ±  0’28  1925’40  ±  479’40a 321’49  ±  16’54a 1681’90  ±  144’69b 799’72  ±  128’67  962’91  ±  5’50  2750’67  ±  126’49
SK-e (n  =  6)  2’23  ±  0’53  3’73  ±  0’05  3’60  ±  0’30  2823’05  ±  479’48  1137’17  ±  4’59  5459’24  ±  349’26  1062’91  ±  100’15  972’92  ±  55’87  7309’65  ±  308’37
CK-e (n  =  6)  1’34  ±  0’26  0’97  ±  0’06d 2’56  ±  0’20c 2306’16  ±  213’07  318’09  ±  7’89d 1622’26  ±  80’87e 597’66  ±  63’27d 1085’72  ±  67’32  2759’15  ±  309’96e
SK-l  (n  =  6)  2’84  ±  0’81  2’67  ±  0’57  3’40  ±  0’86  2584’49  ±  982’12  577’33  ±  296’83  6429’42  ±  858’52  1130’83  ±  239’25  987’90  ±  342’24  2258’26  ±  1652’68
CK-l (n  =  6)  0’60  ±  0’43f 1’49  ±  0’39  3’40  ±  0’38  1921’82  ±  519’61  268’39  1439’36  ±  376’84e 865’95  ±  474’97d 529’73  ±  265’47c 2534’17  ±  178’26
Mean ± SD.
a P < 001.
b P < 0’001. Statistically significant value in regards to S.
c P < 0.05.
d P < 0.01.
e P < 0.001: Statistically significant value in relation to C.




























































Table  5  Tumoral  necrosis  Factor  alpha  (TNF-),  Interleukin-1ß  (IL-1ß),  Monocyte  chemoattractant  protein-1  (MCP-1),  Interleukin-13  (IL-13),  Interleukin-17A  (IL-17A),  Inter-
leukin 4  (IL-4)  and  Interleukin  10  (IL-10)  in  the  ileum,  the  mesenteric  lymph  nodes  and  the  liver  in  in  sham-operated  rats  (S),  in  microsurgical  cholestatic  (C)  rats,  in  sham-operated
(SK-e) and  microsurgical  rats  (CK-e),  which  were  early  administered  Ketotifen  and  in  sham-operated  (SK-l)  and  microsurgical  rats  (CK-l)  that  were  late  administered  Ketotifen.
Groups  TNF-  (pg/100  mg)  IL-1  (pg/100  mg)  MPC-1
Ileum  Mesenteric  nodes  Liver  Ileum  Mesenteric  nodes  Liver  Ileum  Mesenteric  nodes  Liver
S  (n  =  6)  130’24  ±  37’76  129’83  ±  22’48  505’56  ±  65’19  266’02  ±  42’53  431’85  ±  110’88  173’20  ±  30’16  7’30  ±  2’59  29’65  ±  2’22  9’75  ±  1’01
C (n  =  6)  192’27  ±  161’47  141’34  ±  59’21  352’00  ±  255’13  150’87  ±  44’57*  436’10  ±  63’39  249’71  ±  96’64  17’22  ±  6’24*  16’23  ±  4’18  31’83  ±  16’78
SK-e (n  =  6)  40’14  ±  35’60  138’29  ±  32’01  268’82  ±  77’06  154’82  ±  86’66  502’68  ±  79’99  103’73  ±  71’07  6’56  ±  2’80  184’63  ±  26’66  5’70  ±  0’95
CK-e (n  =  6)  36’57  ±  10’78  69’84  ±  17’01oo 125’99  ±  76’08o 170’00  ±  20’53  266’65  ±  81’12  204’58  ±  104’51o 26’93  ±  19’39  94’12  ±  13’06o 26’93  ±  8’56oo
SK-l  (n  =  6)  85’97  ±  20’46  157’66  ±  51’13  2256’32  ±  157’36  431’66  ±  115’12  483’82  ±  194’92oo 884’76  ±  54’86  72’69  ±  30’07  44’07  ±  19’83  235’24  ±  40’10
CK-l (n  =  6)  299’64  ±  32’59++ 76’05  ±  13’34+++ 852’35  ±  505’56++ 140’29  ±  17’35+ 631’04  ±  194’60  495’26  ±  153’06+ 59’10  ±  34’16  110’66  ±  95’03+ 276’61  ±  150’23
Groups IL-13  (pg/100  mg)  IL-17A  (pg/100  mg)  IL-4  (pg/100  mL)
Ileum  Mesenteric  nodes  Liver  Ileum  Mesenteric  nodes  Liver  Ileum  Mesenteric  nodes  Liver
S  (n  =  6)  12’16  ±  2’88  44’62  ±  22’61  20’79  ±  4’96  15’29  ±  4’73  65’72  ±  30’31  33’10  ±  8’77  15’87  ±  7’36  40’77  ±  0’86  53’28  ±  7’56
C (n  =  6)  18’71  ±  8’88  24’78  ±  10’19  24’20  ±  11’25  27’83  ±  16’83  37’91  ±  13’47  40’67  ±  21’68  28’05  ±  13’02*  40’55  ±  12’39  47’58  ±  15’03
SK-e (n  =  6)  8’02  ±  1’53  51’23  ±  21’13  27’14  ±  7’45  12’73  ±  5’77  70’22  ±  28’35  58’03  ±  12’01  13’82  ±  6’29  42’89  ±  1’02  18’15  ±  8’20
CK-e (n  =  6)  15’09  ±  3’35o 87’63  ±  4’65o 21’97  ±  7’91  29’52  ±  6’78o 99’10  ±  17’88o 78’11  ±  20’73o 28’60  ±  9’65o 76’56  ±  3’23oo 60’81  ±  5’42ooo
SK-l  (n  =  6)  20’19  ±  7’48  40’41  ±  24’85  110’26  ±  28’93  25’56  ±  9’87  50’69  ±  42’16  174’14  ±  28’28  0’12  ±  0’01  157’66  ±  51’13  277’77  ±  11’42
CK-l (n  =  6)  35’49  ±  23’09  26’19  ±  46’97  37’38  ±  20’38+++ 40’78  ±  28’23  78’84  ±  77’08  53’44  ±  26’06++ 15’22  ±  18’59++ 76’05  ±  19’34+ 97’22  ±  25’95++
Mean ± SD. * P < 005; Statistically significant value in regards to S, ◦ P < 0.05; ◦ ◦ P < 0.01; oooP < 0.001: Statistically significant value in relation to C; +P < 0.05;++P < 0.01; +++P < 0.001:
Statistically significant value in relation to SK-l.
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Figure  1  a:  Microscopical  Liver  image  in  a  sham-operated  rat  (S;  H&E);  b:  in  one  microsurgical  cholestatic  (C;  H&E)  rat,  in  which
a severe  fibrosis  and  biliary  proliferation  is  shown  (H&E);  c:  in  a  sham-operated  (SK-e)  (Sirius  red  stain)  and  d.  one  microsurgical
rat (CK-e)  (Sirius  red  stain),  which  were  both  early  administered  Ketotifen  (Sirius  red  stain);  d:  in  one  sham-operated  (SK-l)
rat and  e:  in  one  microsurgical  cholestatic  rats  (CK-l)  that  were  both  late  administered  Ketotifen(Sirius  red  stain)  and  f)  liver
areas occupied  by  fibrosis,  determined  by  spectrophotometry  after  Sirius  red  stain  in  the  above  mentioned  groups.  Mean  ±  DE;
***P <  0.001:  statistically  significant  value  in  regards  to  S  group;  P  <  0.001:  statistically  significant  value  in  regards  to  SK-e
group; P  <  0.001:  statistically  significant  value  in  regards  to  SK-l  group.
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Figure  2  Mucosal  mast  cells  (MMC)  and  connective  tissue  mast  cells  (CTMC)  In  the  mesenteric  lymphatic  complex  (a)  and  in  the
liver (b)  in  sham-operated  (SK-e)  and  in  microsurgical  cholestatic  rats  (CK-e),  which  were  both  early  administered  Ketotifen  and
in sham-operated  (SK-l)  rats  and  in  microsurgical  cholestatic  rats  (CK-l)  that  were  both  late  administered  Ketotifen.  Mean  ±  DE;
*P <  0.05:  statistically  significant  value  in  regards  to  S  group;  O  P  <  0.05:  statistically  significant  value  in  regards  to  SK-e  group;
P <  0.05;  P  <  0.01:  statistically  significant  value  in  regards  to  SK-l  group.
Figure  3  Connective  Tissue  mast  cells  [CTMC]  [A]  were  identified  after  stained  with  Toluidin  blue  as  granulated  violet/blue  cells
in the  lymphatic  nodes  of  cholestatic  rats  and  [B]  in  and  in  microsurgical  cholestatic  rats  (CK-e),  which  were  early  administered
Ketotifen. Mucosal  mast  cells  [c]  were  identified  as  rMCP-II  green  immunopositive  cells  in  the  liver  of  cholestatic  rats,  and  [D]  in
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located  in  mucosal  compartments,  express  chymase  (mouse
mast  cell  proteases  mMCP-1and  mMCP-2).  Connective  tis-
sue  type  mast  cells,  located  in  the  skin  and  blood  vessel,
express  chymase,  tryptase  and  carboxypeptidase  A  [25].  The
increase  of  both  populations  of  MCs  in  the  liver  and  of  MMC
in  the  small  bowel  of  rats  with  obstructive  cholestasis  could
indicate  that  they  are  involved  in  the  impairments  devel-
oped  by  these  two  organs.
Therefore,  in  this  experimental  model,  it  could  be
considered  that  two  overlapping  pathological  conditions
participate:  hepatic  insufficiency  caused  by  cholestasis,
which  in  produces  fibrosis  and  portal  hypertension.  There-
fore,  Ketotifen  administration  would  act  differentely  on  one
or  the  other  pathological  conditions.
In  the  liver,  the  inflammatory  response  against  cholestasis
is  considered  a  wound-like  inflammatory  liver  response  [26],
i.e.  portal  fibrosis  and  proliferation  of  the  biliary  epithelial
cells  [27],  and  could  be  mediated  by  mast  cells.  It  is  well
known  that  mast  cells  are  involved  in  the  fibrosis  related
wound-healing  process  [28—30].  Moreover,  there  is  a  pos-
itive  correlation  between  mast  cell  number/activity  and
scar  formation  mediated  by  fibroblasts  [28,30].  Although
data  indicates  that  mast  cells  and  their  mediators  are  ben-
eficial  [31—33]  in  the  different  phases  of  wound  healing,
they  can  also  have  detrimental  roles,  especially  when  CTMC
are  chronically  activated  [29].  There  is  evidence  that  mast
cells  are  involved  in  various  hepatobiliary  disorders,  such
as  chronic  liver  diseases  and  biliary/cholestatic  diseases
[34,35].  This  suggests  that  they  are  at  least  involved  in
inflammation  and  periportal  fibrosis  [12,35—37].  In  addi-
tion,  mast  cells  produce  cytokines  and  growth  factors  that
can  promote  excessive  biliary  epithelial  cells  prolifera-
tion  [29].  This  would  therefore  explain  why  a  reduction
of  fibrosis  is  produced  in  the  cholestatic  rats  after  Keto-
tifen  is  administered.  Since  the  number  of  mast  cells  in
the  Ketotifen-treated  cholestatic  rats  and  those  not  treated
with  Ketotifen  does  not  differ,  the  reduction  of  fibrosis
could  be  attributed  to  extra-hepatic  factors.  Therefore,
the  existence  of  porto-systemic  collateral  circulation  would
reduce  the  effectiveness  of  this  drug  since  it  was  admin-
istered  orally.  Moreover,  oral  administration  during  states
of  portal  hypertension  would  not  be  the  most  appropri-
ate  use  of  this  drug  to  successfully  reach  the  hepatic
circulation  and  stabilize  the  mast  cells,  thus  reducing  its
profibrogenic  activity.  Furthermore,  in  cholestasis,  the  hep-
atic  accumulation  of  bilirubin,  a  potent  anti-oxidant  and
anti-inflammatory  substance  [14,26],  could  be  a  cause  of
fibrogenisis  limitation.  Consequently,  we  must  remember
that  the  effects  of  Ketotifen  when  it  reaches  the  liver
by  systemic  recirculation  through  the  hepatic  artery  mod-
ifies  the  mast  cell  phenotype  and,  therefore  achieves  an
anti-fibrogenic  action  without  changing  the  amount  of  mast
cells.
On  the  contrary,  the  effectiveness  of  Ketotifen  admin-
istered  orally  would  be  greater  for  the  intestine  suffering
portal  hypertension.  The  increase  of  portal  pressure  also
spreads  to  the  post-capillar  venules  of  the  splanchnic
venous  system  and  can  produce  gastrointestinal  impair-Please  cite  this  article  in  press  as:  Aller  M-Á,  et  al.  Mast  cel
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ments  by  mechanotransduction  [38].  In  particular,  the
excessive  mechanical  energy  acting  over  the  gastrointestinal
venous  vascular  wall  would  not  only  affect  the  endothe-







re  in  its  neightborhood,  like  the  gastrointestinal  mast  cells
39]. Thus,  the  increase  of  mast  cells  in  cholestatic  rats  with
ortal  hypertension  could  be  related  to  the  mechanotrans-
uctor  stimulus  caused  by  portal  hypertension.  If  so,  the
ntestinal  inflammatory  activation  of  the  mast  cells  would
avor  the  production  and  release  of  proinflammatory  media-
ors  through  an  array  of  mechanisms,  such  as  degranulation,
xosomes/  extracellular  vesicles,  tunneling  nanotubes,  and
xtracellular  trap  formation  [40].  The  mast  cells  then  turn
nto  mediators  of  the  portal  hypertension  pathology  affect-
ng  the  organism.  The  excess  of  intestinal  MMC  mast  cells,
hrough  the  production  and  release  of  angiogenic  (VEGF)  and
ther  growth  factors,  such  as  basic  fibroblastic  growth  factor
FGF2)  [3,11], in  the  cholestatic  rats,  could  be  related  to  the
evelopment  of  hypertensive  portal  intestinal  vasculopathy.
hus,  the  impact  of  the  portal  hypertension  mediated  by
ast  cells  would  induce  angiogenesis  in  the  gastrointestinal
ract  [38].
Hence,  it  could  be  considered  that  the  mast  cells  in  the
xtrahepatic  cholestatic  rat  collaborate  in  the  proliferation
hase  of  splanchnic  wound  healing  and  in  the  distribution
f  the  two  main  components  that  form  granulation  tissue
hroughout  the  portal  system.  In  other  words,  fibrogenesis
n  the  liver  with  increased  deposition  of  collagen.  In  this
xperimental  model  of  acute-on-chronic  liver  failure,  the
ast  cells  would  therefore  participate  in  the  inflammatory
planchnic  response  involved  in  the  wound  healing  gut-liver
esponse.
Likewise,  due  to  the  close  relationship  that  the  mast
ells  have  with  neurons,  they  would  produce  neurogenic
nflammation  and  portal  hypertensive  encephalopathy  [39].
he  mediators  released  by  the  mast  cells  that  bypass
he  liver  and  reach  the  systemic  circulation  through
he  portosystemic  collateral  vessels  would  also  take  part
17,26]  in  the  development  of  this  type  of  encephalopathy
39].
It  is  known  that  after  antigen  stimulus,  mast  cells
igrate  to  secondary  lymphoid  organs  and  can  present
ntigens  to  the  naïve  T  cells  contributing  to  the  adaptive
mmune  response  [41,42].  Thus,  the  increased  density  of
he  CTMC  in  the  mesenteric  lymph  nodes  found  in  long-
erm  cholestatic  rats  could  be  the  result  of  their  migration
rom  the  hepatic-intestinal  inflamed  tissues.  So,  CTMC  could
ffectively  induce  an  adaptive  immune  response  and  could
odulate  the  development  of  the  splanchnic  inflammatory
esponse  in  rats  with  biliary  fibrosis  and  hypertensive  por-
al  intestinal  vasculopathy.  The  tendency  for  mast  cells  to
ecrease  in  the  mesenteric  lymph  nodes  in  the  cholestatic
ats  treated  with  Ketotifen  (Fig.  4a)  would  suggest  their
educed  ability  to  activate  the  acquired  immunity.  If  so,  the
dministration  of  Ketotifen,  which  reduces  the  number  of
ast  cells  in  the  mesenteric  lymph  nodes,  would  lessen  the
ntestinal  inflammatory  activity  mediated  by  the  acquired
mmunity  and,  therefore  would  lower  the  intestinal  levels
f  proinflammatory  mediators,  such  as  TNF-, IL-17  e  IL-1
Table  5).
In addition,  the  mast  cells,  given  that  they  release  medi-
tors  that  produce  vasodilation  and  vascular  permeability,l-mediated  splanchnic  cholestatic  inflammation.  Clin  Res
e.2019.02.001
ncluding  histamine  and  serotonin  [10],  would  therefore
articipate  in  the  acute-on-chronic  inflammatory  splanch-
ic  response  causing  ascites  [43]. However,  it  cannot  be
uled  out  that  one  of  the  mechanisms  producing  ascites
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Figure  4  a  Mucosal  mast  cells  (MMC)  and  connective  tissue  mast  cells  (CTMC)  in  the  ileum  (a)  and  in  the  spleen  (b)  in  sham-
operated (SK-e)  and  in  microsurgical  cholestatic  rats  (CK-e),  which  were  both  early  administered  Ketotifen  and  in  sham-operated




















































ignificant value  in  regards  to  S  group;  P  <  0.01:  statistically
n  rats  with  hepatic  insufficiency  and  portal  hypertension
s  splanchnic  inflammation  related  to  the  mast  cell  immu-
ity  activation  in  the  mesenteric  lymph  nodes.  Therefore,
he  abovementioned  tendency  of  CTMC  reduction  in  the
esenteric  lymph  nodes  in  the  cholestatic  rats  treated  with
etotifen  would  be  associated  with  ascitic  volume  reduc-
ion.  Likewise,  the  acquired  immunity  developed  by  mast
ells  in  the  mesenteric  lymph  nodes  could  participate  in  hep-
tic  inflammation  and,  in  this  case,  in  reducing  fibrogenesis
ssociated  with  the  improvement  of  the  hepatic  function
fter  the  treatment  with  Ketotifen.
The  increase  of  mast  cells  after  transplantation  has  also
een  involved  in  conditioning  dendritic  cells  to  mediate
llograft  tolerance  [44].  In  addition,  mast  cells  can  also
egulate  T-cell  responses  and  regulatory  T-cell  (Treg)  func-
ionality  after  transplantation.  Consequently,  it  has  been
uggested  that  they  could  regulate  the  balance  between
olerance  and  inflammation  [45,46].The  plasticity  of  mast
ells  suggests  that  the  phenotype  of  these  cells  likely
hanges  over  time.  If  so,  MMC  located  in  epithelium  organs
liver  and  ileum)  could  transform  in  CTMC  when  they  are
n  the  spleen  or  the  mesenteric  lymphatic  complex.  This
ould  allow  mast  cells  to  change  their  function  as  a wound
eals  and  could  help  explain  their  functional  diversity
uring  repair  [28,29,47].  Moreover,  mast  cells,  a  sourcePlease  cite  this  article  in  press  as:  Aller  M-Á,  et  al.  Mast  cel
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f  anti-inflammatory/immunosuppressive  mediators,  could
lso  mediate  inflammation  resolution,  an  active  process  nec-






ficant  value  in  regards  to  SK-l  group.
Consequently,  the  continued  administration  of  Ketotifen
educes  CTMC  in  the  mesenteric  lymph  node  complex,  and
s  associated  with  improved  liver  function  and  a  reduc-
ion  of  ascites  volume.  These  results  suggest  the  possible
nvolvement  of  the  CTMC  located  in  the  secondary  lym-
hoid  splanchnic  organs,  in  the  splanchnic  inflammatory
athology  related  to  obstructive  jaundice.  Consequently,
he  increased  accumulation  of  CTMC  in  the  splanchnic  lymph
odes  appears  to  play  a  pivotal  role  in  portal  hypertension
s  well  as  in  their  pathological  consequences,  including  liver
brosis,  intestinal  angiogenesis  and  ascites.
Lastly,  Ketotifen  as  a  mast  cell  membrane  stabilizer  and
istamine  release  inhibitor  would  cause  an  important  envi-
onmental  change  in  the  splanchnic  area  characteristic  of
he  mast  cell  pattern  switch.  Therefore,  it  must  be  kept
n  mind  that  after  the  administration  of  Ketotifen,  the
ast  cell  phenotype  changes,  which  could  favor  the  anti-
nflammatory  and  proresolutive  role  of  MMC.  It  is  well  known
hat  changes  in  mast  cell  phenotype  can  take  place  during
irtually  all  stages  of  mast  cell  existence,  which  demon-
trates  their  extreme  sensibility  to  environmental  changes
48].
In  conclusion,  our  study  suggests  a relevant  role  of  the
TMC  in  the  secondary  lymphoid  splanchnic  organs  in  indu-
ing  acute-on-chronic  liver  failure  found  in  patients  andl-mediated  splanchnic  cholestatic  inflammation.  Clin  Res
e.2019.02.001
nimals  with  well  compensated  cirrhosis  who  rapidly  deteri-
rate  after  a  precipitating  event  [49], as  well  as  the  resulting
otential  benefit  of  the  constant  treatment  with  Ketotifen
ox  1.
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Mast  cell-mediated  splanchnic  cholestatic  inflammation  
Box  1:  Mast  cells  and  experimental  cholestatic  liver
disease.
Mast  cells  are  a  type  of  inflammatory  cells  involved
in  the  splanchnic  area,  including  the  liver  and  the  gas-
trointestinal  tract  in  chronic  liver  diseases.
Mast  cells  are  involved  in  the  splanchnic  inflamma-
tory  response  related  to  the  liver  diseases  through  an
acquired  immune  response  that  is  reduced  by  Ketotifen
administration.
The  modulation  of  the  mast  cell  inflammatory  func-












of  their  associated  complications,  including  hepatic
fibrosis  and  ascites
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